Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brexpiprazole orally disintegrating tablet
- Development stage
- Phase 4
- Lead developer
- Otsuka Holdings
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Brexpiprazole is a second-generation (atypical) antipsychotic small molecule discovered by Otsuka and jointly developed with Lundbeck. It functions as a serotonin-dopamine activity modulator (SDAM), acting as a partial agonist at the dopamine D2 and D3 receptors and the serotonin 5-HT1A receptor, while also acting as an antagonist at 5-HT2A, 5-HT2B, and 5-HT7 receptors. The orally disintegrating tablet (ODT) formulation is specifically designed to dissolve rapidly in the oral cavity without the need for water, providing an alternative for patients who have difficulty swallowing conventional tablets or for whom adherence is a concern. It is indicated for the treatment of schizophrenia, as an adjunctive therapy for major depressive disorder, and for agitation associated with dementia due to Alzheimer's disease.
- Brand names
- Rexulti
- Other names
- brexpiprazole ODT
02
Targets
ADRA1B (α1B)ADRA2C (α2C)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR7 (5-hydroxytryptamine receptor 7)
Beyond the preview
Go deeper on brexpiprazole orally disintegrating tablet.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brexpiprazole orally disintegrating tablet.